Heightened BMI, significant weight loss goals, type 2 diabetes or prediabetes, and patients who want the most effective pharmaceutical weight loss option currently available, supported by clinical monitoring
In the past, only select GLP-1 medications were covered by Medicare Part D (the programs prescription medication benefit) to help treat type 2 diabetes and cardiovascular disease
Marfanoid features in a child with combined methylmalonic aciduria and homocystinuria (CblC type)
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities (as Zepbound)
Current research is still trying to determine how it can help with age-related diseases such as osteoarthritis and brain diseases (6)
GLP-3 (Reta) Research Applications GIP, GLP-1 and glucagon receptor binding and cAMP-accumulation assays in cells co-expressing the three receptors, where GLP-3 (Reta) is the standard reference triple agonist
